Proactive Access Strategies for Novel Cryptosporidiosis Therapeutics
Cryptosporidiosis is a major cause of parasitic diarrhea in lower income countries disproportionately affecting young children, malnourished populations, and people with compromised immunity. While still underemphasized on the global health agenda, the disease is gradually gaining momentum for therapeutic development. However, the real-world impact of any new medicine will hinge on its effective use in regions that currently face significant access barriers. This Perspective asks what it will take to achieve access to new cryptosporidiosis treatments and outlines strategies to bridge scientific progress with real-world delivery.
Authors
- Jonathan Spector (ORCID: https://orcid.org/0000-0002-4738-8933)
- Paul G. Ashigbie (ORCID: https://orcid.org/0000-0001-8221-6785)
- BRIDGET STUART
- Paul Kelly (ORCID: https://orcid.org/0000-0003-0844-6448)
- Beatrice Amadi (ORCID: https://orcid.org/0000-0001-6363-2943)
- Ujjini H. Manjunatha (ORCID: https://orcid.org/0000-0002-7461-9303)
- Poonum Korpe (ORCID: https://orcid.org/0000-0002-2008-0912)
- Kurt Hanevik (ORCID: https://orcid.org/0000-0002-1466-2326)
Institutions
- Novartis (Switzerland) (CH)
- Johns Hopkins University (US)
- Queen Mary University of London (GB)
- Haukeland University Hospital (NO)
- Novant Health (US)
- Tropical Gastroenterology & Nutrition group (ZM)
- University of Bergen (NO)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1093/infdis/jiag226
- Primary Topic
- Parasitic Infections and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Center for Global Health